Top Page
Shanghai Junshi Biosciences Co., Ltd. Class H
(1877)
Shanghai Junshi Biosciences Co., Ltd. Class H (1877) vs. iShares MSCI Hong Kong ETF (EWH)
Shanghai Junshi Biosciences Co., Ltd. Class H Business Overview & Revenue Model
Shanghai Junshi Biosciences Co., Ltd. Class H Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.95B | 1.50B | 1.45B | 4.02B | 1.59B |
| Gross Profit | 1.54B | 868.16M | 927.21M | 2.77B | 1.22B |
| EBITDA | -935.50M | -2.16B | -2.38B | -422.77M | -1.53B |
| Net Income | -1.28B | -2.28B | -2.58B | -728.18M | -1.67B |
Balance Sheet | |||||
| Total Assets | 10.80B | 11.36B | 12.58B | 11.05B | 8.01B |
| Cash, Cash Equivalents and Short-Term Investments | 2.93B | 3.78B | 6.00B | 3.50B | 3.39B |
| Total Debt | 2.93B | 1.79B | 1.32B | 628.20M | 850.78M |
| Total Liabilities | 4.85B | 4.02B | 2.78B | 2.72B | 2.17B |
| Stockholders Equity | 5.86B | 7.17B | 9.50B | 7.96B | 5.84B |
Cash Flow | |||||
| Free Cash Flow | -2.12B | -2.85B | -2.17B | -1.53B | -2.09B |
| Operating Cash Flow | -1.43B | -2.01B | -1.78B | -641.90M | -1.50B |
| Investing Cash Flow | -892.78M | -892.42M | -467.62M | -1.88B | -697.98M |
| Financing Cash Flow | 1.02B | 681.04M | 4.64B | 2.67B | 4.41B |
Shanghai Junshi Biosciences Co., Ltd. Class H Technical Analysis
Shanghai Junshi Biosciences Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | HK$33.78B | ― | -19.78% | ― | 25.96% | 39.58% | |
46 Neutral | C$190.36M | -4.25 | -8.56% | 3.09% | 13.53% | -1.76% | |
| €3.33B | ― | -32.29% | ― | ― | ― | ||
76 Outperform | HK$27.31B | 30.70 | 31.65% | ― | 4.23% | 47.71% | |
53 Neutral | HK$35.26B | ― | -56.68% | ― | 52.25% | 11.46% | |
51 Neutral | HK$5.94B | 32.78 | 9.52% | ― | 185.36% | ― | |
48 Neutral | HK$26.76B | ― | -253.12% | ― | 330.23% | 59.68% |
Shanghai Junshi Biosciences Co., Ltd. Class H Corporate Events
Shanghai Junshi Biosciences Co., Ltd. announced the successful conclusion of its 2024 Annual General Meeting (AGM), where all proposed resolutions were passed. The AGM, held on June 20, 2025, saw participation from shareholders representing a significant portion of the company’s shares. Key resolutions included the approval of the 2024 financial reports, profit distribution plan, and the appointment of auditors for 2025. The results reflect strong shareholder support and are expected to positively impact the company’s strategic operations and financial planning.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has successfully completed the placement of 41,000,000 new H Shares, raising approximately HK$1,026 million in net proceeds. This capital will primarily be used for the development of innovative drugs, including several bi-specific antibodies and fusion proteins, while also supporting general corporate purposes. The completion of this placement increases the company’s total issued shares and strengthens its position in the biopharmaceutical industry by enhancing its financial resources for ongoing and future projects.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has successfully completed the placement of 41,000,000 new H shares under a general mandate, marking a significant milestone for the company. The placement, which represents approximately 15.75% of all issued H shares and 3.99% of all issued shares of the company, was completed on June 20, 2025, and involved independent professional and institutional investors. This strategic move is expected to enhance the company’s financial position and support its ongoing growth and development in the biopharmaceutical sector.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has announced a change in the book closure period and record date for its 2024 Annual General Meeting (AGM). The book closure period, initially set from June 13 to June 20, 2025, has been revised to end on June 19, 2025, with the record date also moved to June 19, 2025. This adjustment ensures that shareholders listed by the end of June 19, 2025, are eligible to attend and vote at the AGM, aligning with the company’s efforts to maintain transparent and efficient shareholder engagement.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has announced a placement of new H shares under a general mandate, appointing a sole placing agent to facilitate the process. The placement involves issuing 41 million shares at HK$25.35 each, raising approximately HK$1,026 million in net proceeds. This strategic move is expected to enhance the company’s capital base and potentially strengthen its market position.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced that its subsidiary, Shanghai JunTop Biosciences Co., Ltd., received acceptance from the National Medical Products Administration for its investigational new drug application for JT118, a recombinant protein vaccine aimed at preventing monkeypox virus infection. This development marks a significant step in the company’s collaborative efforts with prominent Chinese research institutions to address the lack of approved monkeypox vaccines in China, potentially strengthening its position in the pharmaceutical industry.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced a change in equity holdings, with shareholders holding more than 5% of the company’s shares experiencing a decrease from 9.73% to 8.96%. This change does not breach any commitments or trigger mandatory tender offer obligations, indicating a stable transition in shareholder structure without immediate impact on the company’s strategic plans.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$11.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has announced its 2024 Annual General Meeting to be held in June 2025, where several key proposals will be discussed. These include the approval of financial reports, profit distribution plans, and the issuance of debt financing instruments up to RMB2,500 million to support business development and reduce financing costs, reflecting the company’s strategic focus on leveraging market opportunities.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced adjustments to the allocation of proceeds from its 2022 issuance of A shares, aiming to enhance the efficiency of its R&D projects. The company plans to increase investment in certain sub-projects, such as JS207 and JS107, while reducing funding for others, including JS001 and JS004, reflecting strategic shifts in its drug development priorities.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has announced the closure of its H shares register from June 13 to June 20, 2025, to determine shareholder entitlements for the 2024 annual general meeting. This move is significant for stakeholders as it sets the timeline for share transfers and voting eligibility, impacting shareholder participation in the company’s governance.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has received approval from the National Medical Products Administration for two supplemental new drug applications for its ongericimab injection, a PCSK9-targeted monoclonal antibody. This approval marks the first domestic PCSK9-targeted drug for statin-intolerant patients in China, potentially enhancing the company’s market position in the cardiovascular treatment sector. The approval is based on successful Phase III clinical trials demonstrating significant reductions in LDL-C levels, which is crucial for managing cardiovascular disease risk.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has released its unaudited financial results for the first quarter of 2025, reporting a 31.46% increase in operating income compared to the same period last year. Despite the rise in revenue, the company still reported a net loss attributable to shareholders, although it was reduced compared to the previous year. This financial performance highlights the company’s ongoing efforts to improve its market position and operational efficiency, potentially impacting its stakeholders positively by indicating a trend towards financial recovery.
Shanghai Junshi Biosciences Co., Ltd. has announced its participation in the 2024 Annual Results Briefing for the STAR Market Innovative Drug Sector and the 2025 First Quarterly Results Briefing. This event, scheduled for May 8, 2025, aims to provide investors with a comprehensive understanding of the company’s operating results and financial status for 2024 and the first quarter of 2025. The briefing will be held online, allowing investors to engage interactively and submit questions in advance. This initiative is expected to enhance transparency and strengthen investor relations, potentially impacting the company’s market positioning and stakeholder engagement.
Shanghai Junshi Biosciences Co., Ltd. has announced the appointment of Ms. Wang Yuzhou as the new securities affairs representative, effective immediately. Ms. Wang brings the necessary expertise and qualifications, including a secretary of the board of directors qualification certificate from the STAR Market of Shanghai Stock Exchange, to fulfill her duties. This appointment is part of the company’s compliance with relevant laws and regulations, ensuring effective management and communication with stakeholders.
Shanghai Junshi Biosciences Co., Ltd. announced the approval of its supplemental new drug application for toripalimab as a first-line treatment for unresectable or metastatic melanoma. This approval marks a significant milestone as toripalimab becomes the first domestic anti-PD-1 monoclonal antibody approved for advanced melanoma in China, addressing an urgent clinical need. The approval is based on positive results from the MELATORCH study, which demonstrated improved progression-free survival and overall survival rates compared to traditional chemotherapy. This development enhances Junshi Biosciences’ position in the oncology market and provides a new treatment option for melanoma patients, potentially impacting the company’s market presence and stakeholder interests.
Shanghai Junshi Biosciences Co., Ltd. announced updates regarding the shareholding of its largest shareholder, Mr. Xiong Jun, who is also the chairman and an executive director of the company. Mr. Xiong has entered into new concert party agreements, which have adjusted the composition of the shareholder group, resulting in a 18.67% interest in the company’s total issued share capital. Additionally, Mr. Xiong plans to increase his shareholding by at least RMB100 million over the next 12 months, reflecting his confidence in the company’s future development and long-term investment value. This move may strengthen his influence within the company and potentially impact the company’s market positioning.
Shanghai Junshi Biosciences Co., Ltd. has announced a board meeting scheduled for April 25, 2025, to review and approve the unaudited financial results for the first quarter ending March 31, 2025. This meeting is significant as it provides insights into the company’s financial health and operational performance, which can impact its market positioning and stakeholder confidence.